Developmental Dysplasia of the HipNCT02796768
Automatic Characterization of the Neonatal Hip Using Ultrasound Imaging
An observational study of Developmental Dysplasia of the Hip, run by British Columbia Children's Hospital at 1 site in Canada.
Trial summary
Ultrasound imaging (US), a radiation-free imaging modality, is currently used in diagnosis of developmental dysplasia of the hip (DDH) in infants. The current protocol involves manually identifying specific measures that are prone to error, and may give rise to false positives. Read more about this study
- Who is it for?
- Ages Up to 4 months
- Conditions the study is for
- Developmental Dysplasia of the Hip
- What is being tested?
- 3D US Scanning and 2D US Scanning
- How many people
- 75 participants
- Where
- 1 siteCanada
- Study dates
- Dec 2014to Jun 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 4 months
- All sexes
- No healthy volunteers
- Child
Study population: Infants that have been referred to the Orthopaedic Clinic at our institution for suspected or diagnosed Developmental Dysplasia of the Hip (DDH).
Who may be able to join
- Children with suspected DDH at our institution
- Ages 0 to 4 months of age
Who cannot join
- US not performed at our institution
- No diagnosis of DDH or not suspected of having DDH
- Other congenital hip abnormalities or genetic syndromes
- Patient/family does not live in the Lower Mainland
Trial locations and contacts
1 site in 1 country.
Canada1 site, 1 recruiting
- Recruiting
British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4
Kishore Mulpuri, MBBS, MS(Ortho), MHSc, 6048752054, kmulpuri@cw.bc.ca
About this study
Ultrasound imaging (US), a radiation-free imaging modality, is currently used in diagnosis of developmental dysplasia of the hip (DDH) in infants. The current protocol involves manually identifying specific measures that are prone to error, and may give rise to false positives. We aim to use 2-dimensional (2D) and 3-dimensional (3D) ultrasound imaging to create an automatic measurement procedure that we hope will reduce the errors in measurement and increase reliability.
Read the detailed description
STUDY OBJECTIVES To investigate the use of a novel approach for accurate and automatic extraction of bone, cartilage and muscle surfaces from 3D US images, and to automatically characterize the infant DDH hip. To evaluate the performance of the 3D US-based approach, we will be comparing the results with regular 2D US images of the same patients from the radiology archives at our institution.
HYPOTHESIS We hypothesize that automatically extracted bone/cartilage boundaries can provide useful information about DDH, enable more reliable and reproducible diagnoses, and reduce false diagnostic positives and negatives of DDH. Using 3D US may reveal clinically significant disease or dysplasia metrics that have the potential to change diagnostic procedures.
AIMS:
- To determine if automatically extracted 3D bone/cartilage surfaces provide useful information (i.e., disease or dysplasia metrics) during the assessment of DDH and provide better visualization of the infant hip anatomy in comparison to regular 2D US-based DDH assessment.
- To determine if diagnosing DDH using the 3D US images reduces the operator dependent false positive and false negative rates.
- To determine if 3D US-based dysplasia metrics are as valuable in tracking disease progression as 2D US-based dysplasia metrics.
RESEARCH METHOD Parents and their infants that have been referred to the Orthopaedic Clinic at our institution for suspected or diagnosed DDH will be approached by the Orthopaedic Department's research staff to participate in the study. We are hoping to reach an n=75 as we expect 33% will be lost to follow up. Once eligible infants have been identified by clinical staff, the research staff will outline the study and will obtain informed consent. The parents will be informed of the four additional scan sessions that we would like to collect. Two separate orthopaedic surgeons will each perform one of the 3D and one 2D scan sessions, so as to assess inter-rater reliability. In order to assess intra-rater reliability, each scan session will consist of 2 successive scans.
A major goal of this study is to show that the automated image extraction/analysis by 3D US can reproduce the findings of an expert clinician trained in DDH diagnosis. The 3D images will be processed by using the confidence-weighted local-phase feature based image processing method. Accordingly, the dysplasia metrics can be directly compared between two specialists to determine the feasibility of this approach. Should this method prove to be efficacious, further study could potentially investigate whether this aspect of patient care could be made the responsibility of nurse practitioners.
A secondary goal of this study is to assess how 3D US compares to 2D US in tracking DDH progression. In order to investigate this, we will be giving parents the option to opt in to a second set of US scans if it is necessary for their infant to return to clinic for follow-up treatment. This will not be a mandatory criterion for inclusion into the study. However, as current clinical practice involves checking for DDH progression with 2D US scans, it will provide additional information that could be valuable for comparing the two scanning methods in tracking DDH progression. This option will be presented to parents in the form of a check box on the consent form for them to opt in if they so wish.
DATA ANALYSIS The reliability and accuracy of the 3D image-derived dysplasia metrics will be compared with the standard 2D B-mode US images in terms of variability within inter-rater and intra-rater measurements. For statistical significance of improvement in the diagnostic procedure, we require at least 50 infants with at least one affected hip or suspected affected hip with DDH. We have asked for a recruitment size of 75 as we believe that at least 33% will be lost to follow up. This will be achieved by performing a comparison study between the 2D and 3D US images collected for each patient at each clinic visit. Orthopaedic surgeons from our institution will be asked to identify important features from both (processed and un-processed) US images. For 2D images, the surgeons will measure α and ß angles and percent coverage of the femur. Intra- and inter-rater reliability will be calculated using kappa scores. For 3D images, profiles of α and ß angles and 3-dimensional percentage coverage of the femur (i.e. volume coverage instead of surface coverage), will be measured. These manual measurements will be compared to the measurements determined by automatic image extraction and analysis to test for improvement in diagnostic procedure.
- Conditions
- Developmental Dysplasia of the Hip
- Being tested
- 3D US Scanning, 2D US Scanning
- Medical subject headings
- Developmental Dysplasia of the Hip
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
3D US ScanningOther
3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
2D US ScanningOther
2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
| Study group | Role | What they receive |
|---|---|---|
| Participants | Study participants will be 0 to 4 months of age and undergoing DDH screening. They will have the following scans:
BASELINE - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2, 1 2D US scanning session of right and left hip by Specialist 1, 1 2D US scanning session of right and left hip by Specialist 2.
FOLLOW-UP (OPTIONAL) - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2,
1 2D US scanning session of right and left hip by Specialist 1,
1 2D US scanning session of right and left hip by Specialist 2. Receives: Other: 3D US Scanning; Other: 2D US Scanning |
What is being measured
The primary outcome is the main question the study is designed to answer.
Alpha angles automatically extracted from 3D US images as a measure of dysplasia of the infant hip
Measured: Baseline
Alpha angles automatically extracted/measured from 2D US images as a measure of dysplasia of the infant hip
Measured: Baseline
Secondary outcomes (4)
Beta angles automatically extracted from 3D US images as a measure of dysplasia of the infant hip
Measured: Baseline
Beta angles automatically extracted/measured from 2D US images as a measure of dysplasia of the infant hip
Measured: Baseline
Femoral head coverage automatically extracted from 3D US images as a measure of dysplasia of the infant hip
Measured: Baseline
Femoral head coverage automatically extracted/measured from 2D US images as a measure of dysplasia of the infant hip
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2016 (estimated)
- Study startDec 2014
- Primary completionJun 2017 (estimated)
- Study completionJun 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Developmental Dysplasia of the HipStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- British Columbia Children's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of British Columbia
- Responsible party
- Principal investigator, Kishore Mulpuri, British Columbia Children's Hospital
- Investigators
- Kishore Mulpuri, MBBS, MS(Ortho), MHSc, Principal investigator, Provincial Health Services Authority British ColumbiaAntony Hodgson, BASc, MASc, PhD, Principal investigator, University of British ColumbiaAnthony Cooper, BSc, MBChB, FRCS, Principal investigator, Provincial Health Services Authority British ColumbiaRafeef Abugharbieh, BSc, MSc, PhD, Principal investigator, University of British Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02796768
- Sponsor's protocol ID
- H14-01448
- Status last verified
- Jun 2016
- First submitted
- 26 May 2016
- Last updated
- 13 Jun 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jun 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Automatic Characterization of the Neonatal Hip Using Ultrasound Imaging
- ClinicalTrials.gov ID
- NCT02796768
- Acronym / sponsor ID
- H14-01448
- Conditions
- Developmental Dysplasia of the Hip
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- British Columbia Children's HospitalUniversity, hospital or other
- Collaborators
- University of British Columbia
- Study start
- Dec 2014
- Primary completion
- Jun 2017 (estimated)
- Study completion
- Jun 2017 (estimated)
- First posted
- 13 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ultrasound imaging (US), a radiation-free imaging modality, is currently used in diagnosis of developmental dysplasia of the hip (DDH) in infants. The current protocol involves manually identifying specific measures that are prone to error, and may give rise to false positives. We aim to use 2-dimensional (2D) and 3-dimensional (3D) ultrasound imaging to create an automatic measurement procedure that we hope will reduce the errors in measurement and increase reliability.
Detailed description
STUDY OBJECTIVES To investigate the use of a novel approach for accurate and automatic extraction of bone, cartilage and muscle surfaces from 3D US images, and to automatically characterize the infant DDH hip. To evaluate the performance of the 3D US-based approach, we will be comparing the results with regular 2D US images of the same patients from the radiology archives at our institution.
HYPOTHESIS We hypothesize that automatically extracted bone/cartilage boundaries can provide useful information about DDH, enable more reliable and reproducible diagnoses, and reduce false diagnostic positives and negatives of DDH. Using 3D US may reveal clinically significant disease or dysplasia metrics that have the potential to change diagnostic procedures.
AIMS:
- To determine if automatically extracted 3D bone/cartilage surfaces provide useful information (i.e., disease or dysplasia metrics) during the assessment of DDH and provide better visualization of the infant hip anatomy in comparison to regular 2D US-based DDH assessment.
- To determine if diagnosing DDH using the 3D US images reduces the operator dependent false positive and false negative rates.
- To determine if 3D US-based dysplasia metrics are as valuable in tracking disease progression as 2D US-based dysplasia metrics.
RESEARCH METHOD Parents and their infants that have been referred to the Orthopaedic Clinic at our institution for suspected or diagnosed DDH will be approached by the Orthopaedic Department's research staff to participate in the study. We are hoping to reach an n=75 as we expect 33% will be lost to follow up. Once eligible infants have been identified by clinical staff, the research staff will outline the study and will obtain informed consent. The parents will be informed of the four additional scan sessions that we would like to collect. Two separate orthopaedic surgeons will each perform one of the 3D and one 2D scan sessions, so as to assess inter-rater reliability. In order to assess intra-rater reliability, each scan session will consist of 2 successive scans.
A major goal of this study is to show that the automated image extraction/analysis by 3D US can reproduce the findings of an expert clinician trained in DDH diagnosis. The 3D images will be processed by using the confidence-weighted local-phase feature based image processing method. Accordingly, the dysplasia metrics can be directly compared between two specialists to determine the feasibility of this approach. Should this method prove to be efficacious, further study could potentially investigate whether this aspect of patient care could be made the responsibility of nurse practitioners.
A secondary goal of this study is to assess how 3D US compares to 2D US in tracking DDH progression. In order to investigate this, we will be giving parents the option to opt in to a second set of US scans if it is necessary for their infant to return to clinic for follow-up treatment. This will not be a mandatory criterion for inclusion into the study. However, as current clinical practice involves checking for DDH progression with 2D US scans, it will provide additional information that could be valuable for comparing the two scanning methods in tracking DDH progression. This option will be presented to parents in the form of a check box on the consent form for them to opt in if they so wish.
DATA ANALYSIS The reliability and accuracy of the 3D image-derived dysplasia metrics will be compared with the standard 2D B-mode US images in terms of variability within inter-rater and intra-rater measurements. For statistical significance of improvement in the diagnostic procedure, we require at least 50 infants with at least one affected hip or suspected affected hip with DDH. We have asked for a recruitment size of 75 as we believe that at least 33% will be lost to follow up. This will be achieved by performing a comparison study between the 2D and 3D US images collected for each patient at each clinic visit. Orthopaedic surgeons from our institution will be asked to identify important features from both (processed and un-processed) US images. For 2D images, the surgeons will measure α and ß angles and percent coverage of the femur. Intra- and inter-rater reliability will be calculated using kappa scores. For 3D images, profiles of α and ß angles and 3-dimensional percentage coverage of the femur (i.e. volume coverage instead of surface coverage), will be measured. These manual measurements will be compared to the measurements determined by automatic image extraction and analysis to test for improvement in diagnostic procedure.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants | – | Other: 3D US Scanning, Other: 2D US ScanningStudy participants will be 0 to 4 months of age and undergoing DDH screening. They will have the following scans: BASELINE - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2, 1 2D US scanning session of right and left hip by Specialist 1, 1 2D US scanning session of right and left hip by Specialist 2. FOLLOW-UP (OPTIONAL) - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2, 1 2D US scanning session of right and left hip by Specialist 1, 1 2D US scanning session of right and left hip by Specialist 2. |
Who may qualify
- Ages
- Up to 4 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Infants that have been referred to the Orthopaedic Clinic at our institution for suspected or diagnosed Developmental Dysplasia of the Hip (DDH).
Key inclusion criteria (2 listed)
- Children with suspected DDH at our institution
- Ages 0 to 4 months of age
Key exclusion criteria (4 listed)
- US not performed at our institution
- No diagnosis of DDH or not suspected of having DDH
- Other congenital hip abnormalities or genetic syndromes
- Patient/family does not live in the Lower Mainland
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 3D US Scanning3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant. | Other | Participants |
| 2D US Scanning2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant. | Other | Participants |
Primary outcome
Alpha angles automatically extracted from 3D US images as a measure of dysplasia of the infant hip
Time frame: Baseline
Alpha angles automatically extracted/measured from 2D US images as a measure of dysplasia of the infant hip
Time frame: Baseline
4 secondary outcomes
Beta angles automatically extracted from 3D US images as a measure of dysplasia of the infant hip
Time frame: Baseline
Beta angles automatically extracted/measured from 2D US images as a measure of dysplasia of the infant hip
Time frame: Baseline
Femoral head coverage automatically extracted from 3D US images as a measure of dysplasia of the infant hip
Time frame: Baseline
Femoral head coverage automatically extracted/measured from 2D US images as a measure of dysplasia of the infant hip
Time frame: Baseline
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jun 2016.
- Individual participant dataSharing planned: No
Related trials for Developmental Dysplasia of the Hip
Recruiting
SIRI Levels Following PENG Block in Pediatric Hip Surgery
Hip Dysplasia
RecruitingPhase 4
PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
Hip Disease, Hip Dysplasia
Recruiting
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
Osteoarthritis, Traumatic Arthritis
Not yet recruitingObservational study
3D-Printed Pelvic Models for Planning Complex Total Hip Arthroplasty
Developmental Dysplasia of the Hip, Acetabular Bone Loss
Active, not recruitingObservational study
The Medacta Quadra-P Anteverted Study
Arthrosis, Traumatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kishore Mulpuri, MBBS, MS(Ortho), MHSc principal investigator
Provincial Health Services Authority British Columbia
Antony Hodgson, BASc, MASc, PhD principal investigator
University of British Columbia
Anthony Cooper, BSc, MBChB, FRCS principal investigator
Provincial Health Services Authority British Columbia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Developmental Dysplasia of the Hip, run by British Columbia Children's Hospital at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Kishore Mulpuri, MBBS, MS(Ortho), MHSc (6048752054, kmulpuri@cw.bc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Alpha angles automatically extracted from 3D US images as a measure of dysplasia of the infant hip (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jun 2016.